- Home
- CCAP vs RCKT Comparison
CCAP vs RCKT Comparison
Compare CCAP & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CCAP | RCKT |
|---|---|---|
| Founded | 2015 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 492.4M | 428.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CCAP | RCKT |
|---|---|---|
| Price | $13.47 | $4.66 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 14 |
| Target Price | $16.33 | ★ $29.65 |
| AVG Volume (30 Days) | 192.0K | ★ 2.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 13.66% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.18 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.56 | $2.19 |
| 52 Week High | $17.97 | $9.11 |
Technical Indicators
Market Signals| Indicator | CCAP | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 45.72 | 70.36 |
| Support Level | $13.18 | $2.99 |
| Resistance Level | $14.70 | N/A |
| Average True Range (ATR) | 0.44 | 0.32 |
| MACD | 0.02 | 0.12 |
| Stochastic Oscillator | 56.13 | 70.33 |
Price Performance
Historical ComparisonAbout CCAP Crescent Capital BDC Inc.
Crescent Capital BDC Inc is a business development company structured as an externally managed, closed-end, non-diversified management investment company. The company's primary investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation through debt and related equity investments. It will seek to achieve its investment objectives by investing in secured debt (including senior secured, unitranche, and second lien debt) and unsecured debt (including senior unsecured, mezzanine, and subordinated debt), as well as related equity securities of private U.S. middle-market companies.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.